Glucagon-Like-Peptide-1 Agonists, like Ozempic, have become extremely popular for weight loss. Here are some of the side ...

Projections for the near future indicate that the glucagon-like peptide GLP-1 agonists weight loss drugs market size will continue to surge, reaching $28.91 billion in 2029 at a CAGR of 16.6%.

About The Study: In this cohort study, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) among patients with diabetes was associated with a 2-fold higher risk of incident ...

Glucagon-like peptide (GLP)-1 is an intestinally produced peptide hormone [1] that stimulates insulin secretion, [2] inhibits glucagon secretion, [2] reduces plasma glucose levels in patients with ...

GLP-1RAs (glucagon-like peptide-1 receptor agonists) have consistently demonstrated a protective effect against ischemic stroke. However, whether this benefit also extends to nontraumatic ...

Background Shorter half-life glucagon-like peptide-1 receptor agonists (GLP-1 RAs) delay gastric emptying (DGE) more than GLP-1 RAs with longer half-lives. DGE is a known risk factor for ...

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...